FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038982872> ?p ?o ?g. }

• W2038982872 endingPage "747" @default.
• W2038982872 startingPage "739" @default.
• W2038982872 abstract "Objective:To examine how changes in the medication possession ratio (MPR) affect the probability of multiple sclerosis (MS) relapses and total and MS-related charges among patients treated with glatiramer acetate (GA).Methods:Data were obtained from i3 InVisionTM Data Mart for January 1, 2006 through March 31, 2010. Patients were included if they were diagnosed with MS, initiated therapy with GA, and had continuous insurance coverage from 6 months prior through 24 months after initial use of GA (n = 839). Multivariate regressions which controlled for patient characteristics examined the association between achievement of alternative MPR goals and patient relapses and charges.Results:Patients who achieved an MPR of at least 0.7 had significantly lower odds of relapse than those with MPR thresholds below 0.7, with achievement of a threshold of 0.7, 0.8, or 0.9, associated with an odds ratio of relapse of 0.545 (95% CI = 0.351–0.824), 0.568 (95% CI = 0.371–0.870), and 0.421 (95% CI = 0.260–0.679), respectively. Attaining higher MPR thresholds resulted in larger reductions in direct medical charges, excluding GA and other MS-related drugs. MPR of 0.25 was associated with $1699 lower 2-year total direct medical charges (p = 0.009) while a threshold of 0.95 was associated with $2136 lower total charges (p < 0.001), compared to patients not reaching these respective thresholds. MPR of 0.90 was associated with $986 lower MS-related charges than for those with MPR < 0.90 (p = 0.050). Results also revealed an association between patient adherence to GA and statistically significant reductions in charges for specific components of care.Limitations:Results are generalizable only to patients with medical and prescription benefit coverage without regard for functional status.Conclusions:As adherence improved the odds of relapse decreased and charge offsets generally increased. Results suggest that, despite higher costs associated with increased usage of GA, patient outcomes are improved and there are cost-offsets associated with adherent use of GA." @default.
• W2038982872 created "2016-06-24" @default.
• W2038982872 creator A5002705317 @default.
• W2038982872 creator A5007435835 @default.
• W2038982872 creator A5024417105 @default.
• W2038982872 creator A5087572907 @default.
• W2038982872 date "2011-01-01" @default.
• W2038982872 modified "2023-09-26" @default.
• W2038982872 title "The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate" @default.
• W2038982872 cites W133857840 @default.
• W2038982872 cites W1967253329 @default.
• W2038982872 cites W1967507425 @default.
• W2038982872 cites W1968456700 @default.
• W2038982872 cites W1970751485 @default.
• W2038982872 cites W1981761303 @default.
• W2038982872 cites W1984185015 @default.
• W2038982872 cites W1985883593 @default.
• W2038982872 cites W2002263135 @default.
• W2038982872 cites W2005506388 @default.
• W2038982872 cites W2014094373 @default.
• W2038982872 cites W2019641262 @default.
• W2038982872 cites W2026933034 @default.
• W2038982872 cites W2028483867 @default.
• W2038982872 cites W2030251045 @default.
• W2038982872 cites W2033175786 @default.
• W2038982872 cites W2035876673 @default.
• W2038982872 cites W2037260636 @default.
• W2038982872 cites W2053121650 @default.
• W2038982872 cites W2059101486 @default.
• W2038982872 cites W2059220200 @default.
• W2038982872 cites W2061166054 @default.
• W2038982872 cites W2071683523 @default.
• W2038982872 cites W2072965568 @default.
• W2038982872 cites W2075033945 @default.
• W2038982872 cites W2080458330 @default.
• W2038982872 cites W2080543874 @default.
• W2038982872 cites W2083061008 @default.
• W2038982872 cites W2084219024 @default.
• W2038982872 cites W2088546205 @default.
• W2038982872 cites W2099210971 @default.
• W2038982872 cites W2100721517 @default.
• W2038982872 cites W2115989506 @default.
• W2038982872 cites W2123038985 @default.
• W2038982872 cites W2129906534 @default.
• W2038982872 cites W2131902490 @default.
• W2038982872 cites W2139062201 @default.
• W2038982872 cites W2144095014 @default.
• W2038982872 cites W2153409966 @default.
• W2038982872 cites W2164331547 @default.
• W2038982872 cites W2166983650 @default.
• W2038982872 cites W2171570337 @default.
• W2038982872 cites W2984556666 @default.
• W2038982872 cites W4253042937 @default.
• W2038982872 cites W4376453208 @default.
• W2038982872 cites W914135345 @default.
• W2038982872 doi "https://doi.org/10.3111/13696998.2011.618517" @default.
• W2038982872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21913796" @default.
• W2038982872 hasPublicationYear "2011" @default.
• W2038982872 type Work @default.
• W2038982872 sameAs 2038982872 @default.
• W2038982872 citedByCount "34" @default.
• W2038982872 countsByYear W20389828722012 @default.
• W2038982872 countsByYear W20389828722013 @default.
• W2038982872 countsByYear W20389828722014 @default.
• W2038982872 countsByYear W20389828722015 @default.
• W2038982872 countsByYear W20389828722016 @default.
• W2038982872 countsByYear W20389828722017 @default.
• W2038982872 countsByYear W20389828722018 @default.
• W2038982872 countsByYear W20389828722019 @default.
• W2038982872 countsByYear W20389828722020 @default.
• W2038982872 countsByYear W20389828722021 @default.
• W2038982872 countsByYear W20389828722022 @default.
• W2038982872 crossrefType "journal-article" @default.
• W2038982872 hasAuthorship W2038982872A5002705317 @default.
• W2038982872 hasAuthorship W2038982872A5007435835 @default.
• W2038982872 hasAuthorship W2038982872A5024417105 @default.
• W2038982872 hasAuthorship W2038982872A5087572907 @default.
• W2038982872 hasConcept C126322002 @default.
• W2038982872 hasConcept C143095724 @default.
• W2038982872 hasConcept C151956035 @default.
• W2038982872 hasConcept C156957248 @default.
• W2038982872 hasConcept C203014093 @default.
• W2038982872 hasConcept C2778577042 @default.
• W2038982872 hasConcept C2780640218 @default.
• W2038982872 hasConcept C44249647 @default.
• W2038982872 hasConcept C71924100 @default.
• W2038982872 hasConceptScore W2038982872C126322002 @default.
• W2038982872 hasConceptScore W2038982872C143095724 @default.
• W2038982872 hasConceptScore W2038982872C151956035 @default.
• W2038982872 hasConceptScore W2038982872C156957248 @default.
• W2038982872 hasConceptScore W2038982872C203014093 @default.
• W2038982872 hasConceptScore W2038982872C2778577042 @default.
• W2038982872 hasConceptScore W2038982872C2780640218 @default.
• W2038982872 hasConceptScore W2038982872C44249647 @default.
• W2038982872 hasConceptScore W2038982872C71924100 @default.
• W2038982872 hasIssue "6" @default.
• W2038982872 hasLocation W20389828721 @default.
• W2038982872 hasLocation W20389828722 @default.

• next